Formoterol, an inhaled long‐acting β2‐agonist, has been used as a bronchodilator combating asthma and COPD for decades.[31, 32] To explore the mechanisms underlying formoterol protection in EPO‐induced AAA, we examined the expression of β2AR in mouse VSMCs. This evidence concerns the gene EPO and chronic obstructive pulmonary disease.